Man Group
APGE

Man Group’s Apogee Therapeutics APGE Stock Holding History

Man Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7M Buy
397,000
+355,185
+849% +$32M 0.08% 241
2026
Q1 		$3.52M Buy
41,815
+30,652
+275% +$2.23M 0.01% 1324
2025
Q4 		$843K Buy
+11,163
New +$703K ﹤0.01% 1725

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Man Group's APGE Position: Q2 2026 in Review

Man Group increased its Apogee Therapeutics (APGE) stake by 849% in Q2 2026, buying an estimated $32M and bringing the position to 397,000 shares worth $52.7M. The position accounts for 0.08% of the portfolio, ranked #241.

Man Group first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Man Group held 397,000 shares of Apogee Therapeutics worth $52.7M as of Q2 2026.
  • Man Group bought 355,185 Apogee Therapeutics shares in Q2 2026, an estimated $32M.
  • Apogee Therapeutics made up 0.08% of Man Group's portfolio in Q2 2026, its #241 holding.
  • Man Group first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.